Trends in antimicrobial resistance in Neisseria gonorrhoeae in the USA: The Gonococcal Isolate Surveillance Project (GISP), January 2006-June 2012

Sexually Transmitted Infections

Volumn 89, Issue SUPPL. 4, 2013, Pages

  Kirkcaldy, Robert D ^a   Kidd, Sarah ^a   Weinstock, Hillard S ^a   Papp, John R ^a   Bolan, Gail A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; DOXYCYCLINE; ERYTHROMYCIN; PENICILLIN DERIVATIVE; SPECTINOMYCIN; TETRACYCLINE;

ADD ON THERAPY; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; GONORRHEA; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; PENICILLIN RESISTANCE; PRIORITY JOURNAL; SENTINEL SURVEILLANCE; UNITED STATES;

ANTIMICROBIAL RESISTANCE; NEISSERIA GONORRHOEA; SURVEILLANCE;

ADULT; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; EPIDEMIOLOGICAL MONITORING; FEMALE; GONORRHEA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; UNITED STATES; YOUNG ADULT;

EID: 84891859404     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sextrans-2013-051162     Document Type: Article

References (33)

1. Centers for Disease Control and Prevention. Summary of notifiable diseases-United States, 2010. MMWR 2012;59:1-111.
2. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2011. Atlanta: U.S. Department of Health and Human Services, 2012.
3. Satterwhite C, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: Prevalence and incidence estimates, 2008. Sex Transm Dis 2013;40:187-93.
4. Kampmeier RH. Introduction of sulfonamide therapy for gonorrhea. Sex Transm Dis 1983;10:81-4. (Pubitemid 13036479)
5. Centers for Disease Control and Prevention. Antibiotic-resistant strains of Neisseria gonorrhoeae. Policy guidelines for detection, management, and control. MMWR 1987;36(5S):1S-18S.
6. Centers for Disease Control and Prevention. 1989 Sexually transmitted diseases treatment guidelines. MMWR 1989;38(S-8):1-43.
7. Centers for Disease Control and Prevention. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae-Hawaii and California, 2001. MMWR 2002;51:1041-4.
8. Centers for Disease Control and Prevention. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men-United States, 2003, and revised recommendations for treatment, 2004. MMWR 2004;53:335-8.
9. Centers for Disease Control and Prevention. Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones are no longer recommended for treatment of gonococcal infections. MMWR 2007;56:332-6.
10. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012;7:1401-22.
11. Centers for Disease Control and Prevention. Cephalosporin susceptibility among Neisseria gonorrhoeae isolates-United States, 2000-2010. MMWR 2011;60:873-7.
12. Centers for Disease Control and Prevention. Update to CDC's sexually transmitted diseases treatment guidelines, 2010: Oral cephalosporins no longer recommended for treatment of gonococcal infections. MMWR 2012;61:590-4.
13. Schwarz S, Zenilman J, Schnell D, et al. National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. JAMA 1990;264:1413-17. (Pubitemid 20331936)
14. Centers for Disease Control and Prevention. Gonococcal Isolate Surveillance Project (GISP) Protocol. 2010. http://www.cdc.gov/std/gisp/GISP- Protocol07-15-2010.pdf
15. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-first informational supplement. CLSI document M100-S21. Wayne, PA: Clinical and Laboratory Standards Institute, 2011.
16. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2010. Atlanta: U.S. Department of Health and Human Services, 2011.
17. Kirkcaldy R, Zaidi A, Hook E, et al. Neisseria gonorrhoeae antimicrobial resistance among men who have sex with men and men who have sex exclusively with women: The gonococcal isolate surveillance project, 2005-2010. Ann Intern Med 2013;158(5 Pt 1):321-8.
18. Dowell D, Tian L, Stover J, et al. Changes in fluoroquinolone use for gonorrhea following publication of revised treatment guidelines. Am J Public Health 2012;102:148-55.
19. Unemo M, Shafer W. Antibiotic resistance in Neisseria gonorrhoeae: Origin, evolution, and lessons learned for the future. Ann N Y Acad Sci 2011;1230:E19-28.
20. Kunz A, Begum A, Wu H, et al. Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations. JID 2012;205:1821-9.
21. Moran J, Levine W. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995;20(Suppl 1):S57-65.
22. Perine P, Morton R, Piot P, et al. Epidemiology and treatment of penicillinaseproducing Neisseria gonorrhoeae. Sex Transm Dis 1979;6:152-8.
23. Hottes T, Lester R, Hoang LM, et al. Cephalosporin and azithromycin susceptibility in Neisseria gonorrhoeae isolates by site of infection, British Columbia, 2006 to 2011. Sex Transm Dis 2013;40:46-51.
24. Manhart L, ARal S, Holmes K, et al. Influence of study population on the identification of risk factors for sexually transmitted diseases using a case-control design: The example of gonorrhea. Am J Epidemiol 2004;160:393-402. (Pubitemid 39045271)
25. Porter C, Thompson D, Erbelding E. Differences in demographics and risk factors among men attending public v non-public STD clinics in Baltimore, Maryland. Sex Transm Infect 2004;80:488-91. (Pubitemid 39627254)
26. Centers for Disease Control and Prevention. 1993 Sexually Transmitted Diseases Treatment Guidelines. MMWR 1993;42(RR-14).
27. Centers for Disease Control and Prevention. 1998 Guidelines for Treatment of Sexually Transmitted Diseases. MMWR 1998;47(RR-1).
28. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines 2002. MMWR 2002;51(RR-6).
29. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2006. MMWR 2006;55(RR-11).
30. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR 2010;59(RR-12).
31. Dicker L, Mosure D, Steece R, et al. Laboratory tests used in US public health laboratories for sexually transmitted diseases, 2000. Sex Transm DIs 2004;31:259-64. (Pubitemid 38542653)
32. Dicker L, Mosure D, Steece R, et al. Testing for sexually transmitted diseases in U.S. public health laboratories in 2004. Sex Transm DIs 2007;34:41-6. (Pubitemid 46041507)
33. Yee E, Satterwhite C, Braxton J, et al. Sexually transmitted diseases testing practices in the US in public health laboratories, 2007. International Society for Sexually Transmitted Diseases Research Conference. London, UK, 2009 (poster presentation).